Trial Profile

A Multicenter, Randomized, Double-Blind, Active-Parallel-Controlled, Phase 3 Clinical Study to Investigate the Efficacy and Safety of DWP14012 in the Treatment of Reflux Esophagitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Jul 2023 According to a Daewoong Pharmaceuticals, company has submitted the New Drug Application (NDA) for Fexuprazan to the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA), based on the results of Phase 3 clinical trials for GERD treatment conducted on 332 patients with erosive esophagitis in China.
19 May 2023 Results of this study presented at the Digestive Disease Week 2023 (DDW 2023) held in Chicago, USA.
19 May 2023 Results presented in a Daewoong Pharmaceutical Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com